Sign Out
Asthma: Fluticasone furoate + Vilanterol (as trifenatate) (Relvar Ellipta) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
COPD (Chronic Obstructive Pulmonary Disease): Fluticasone furoate + Vilanterol (as trifenatate) (Relvar Ellipta) is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
Continue with Google